EVI1 induces myelodysplastic syndrome in mice

被引:156
作者
Buonamici, S
Li, DL
Chi, YQ
Zhao, R
Wang, XR
Brace, L
Ni, HY
Saunthararajah, Y
Nucifora, G
机构
[1] Univ Illinois, Dept Pathol, Chicago, IL 60607 USA
[2] Univ Illinois, Ctr Canc, Chicago, IL 60607 USA
关键词
D O I
10.1172/JCI200421716
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Myelodysplasia is a hematological disease in which genomic abnormalities accumulate in a hematopoietic stem cell leading to severe pancytopenia, multilineage differentiation impairment, and bone marrow (BM) apoptosis. Mortality in the disease results from pancytopenia or transformation to acute myeloid leukemia. There are frequent cytogenetic abnormalities, including deletions of chromosomes 5, 7, or both. Recurring chromosomal translocations in myelodysplasia are rare, but the most frequent are the t(3;3)(q21;q26) and the inv(3)(q21q26), which lead to the inappropriate activation of the EVI1 gene located at 3q26. To better understand the role of EVI1 in this disease, we have generated a murine model of EVI1-positive myelodysplasia by BM infection and transplantation. We find that EVI1 induces a fatal disease of several stages that is characterized by severe pancytopenia. The disease does not progress to acute myeloid leukemia. Comparison of in vitro and in vivo results suggests that EVI1 acts at two levels. The immediate effects of EVI1 are hyperproliferation of BM cells and downregulation of EpoR and c-Mpl, which are important for terminal erythroid differentiation and platelet formation. These defects are not fatal, and the mice survive for about 10 months with compensated hematopoiesis. Over this time, compensation fails, and the mice succumb to fatal peripheral cytopenia.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 33 条
  • [1] Alessandrino EP, 2001, HAEMATOLOGICA, V86, P1124
  • [2] Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Bounamici, S
    Ottaviani, E
    Testoni, N
    Montefusco, V
    Visani, G
    Bonifazi, F
    Amabile, M
    Terragna, C
    Ruggeri, D
    Piccaluga, PP
    Isidori, A
    Malagola, M
    Baccarani, M
    Tura, S
    Martinelli, G
    [J]. BLOOD, 2002, 99 (02) : 443 - 449
  • [3] The role of EVI1 in normal and leukemic cells
    Buonamici, S
    Chakraborty, S
    Senyuk, V
    Nucifora, G
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (02) : 206 - 212
  • [4] Transcriptional regulation of erythropoiesis: an affair involving multiple partners
    Cantor, AB
    Orkin, SH
    [J]. ONCOGENE, 2002, 21 (21) : 3368 - 3376
  • [5] Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles
    Chakraborty, S
    Senyuk, V
    Sitailo, S
    Chi, YQ
    Nucifora, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (48) : 44936 - 44943
  • [6] EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity
    Chi, YQ
    Senyuk, V
    Chakraborty, S
    Nucifora, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) : 49806 - 49811
  • [7] Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML
    Cuenco, GM
    Nucifora, G
    Ren, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) : 1760 - 1765
  • [8] 4 OF THE 7 ZINC FINGERS OF THE EVI-1 MYELOID-TRANSFORMING GENE ARE REQUIRED FOR SEQUENCE-SPECIFIC BINDING TO GA(C/T)AAGA(T/C)AAGATAA
    DELWEL, R
    FUNABIKI, T
    KREIDER, BL
    MORISHITA, K
    IHLE, JN
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) : 4291 - 4300
  • [9] Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family
    Fears, S
    Mathieu, C
    ZeleznikLe, N
    Huang, S
    Rowley, JD
    Nucifora, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) : 1642 - 1647
  • [10] FUNABIKI T, 1990, ONCOGENE, V5, P925